These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 15782540)

  • 1. Antibodies to tumor necrosis factor-alpha in the treatment of Crohn's disease.
    Brown SJ; Abreu MT
    Curr Opin Drug Discov Devel; 2005 Mar; 8(2):160-8. PubMed ID: 15782540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of ulcerative colitis and Crohn's disease with monoclonal antibody].
    Asakura H
    Nihon Rinsho; 2002 Mar; 60(3):531-8. PubMed ID: 11904969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of a 99mTc labeled anti-TNFalpha monoclonal antibody in Crohn's disease: in vitro and in vivo studies.
    D'Alessandria C; Malviya G; Viscido A; Aratari A; Maccioni F; Amato A; Scopinaro F; Caprilli R; Signore A
    Q J Nucl Med Mol Imaging; 2007 Dec; 51(4):334-42. PubMed ID: 17464276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study.
    Asteria CR; Ficari F; Bagnoli S; Milla M; Tonelli F
    Scand J Gastroenterol; 2006 Sep; 41(9):1064-72. PubMed ID: 16938720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term partial remission of autoimmune thrombocytopenia in a patient treated with the anti-tumor necrosis factor-alpha antibody infliximab for refractory fistulizing Crohn's disease.
    de Rossi TM; Krauss N; Voll RE; Nägel A; Weidenhiller M; Konturek PC; Hahn EG; Raithel M
    Digestion; 2008; 78(4):195-200. PubMed ID: 19122456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn's disease.
    Schinzari F; Armuzzi A; De Pascalis B; Mores N; Tesauro M; Melina D; Cardillo C
    Clin Pharmacol Ther; 2008 Jan; 83(1):70-6. PubMed ID: 17507924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease.
    Hlavaty T; Pierik M; Henckaerts L; Ferrante M; Joossens S; van Schuerbeek N; Noman M; Rutgeerts P; Vermeire S
    Aliment Pharmacol Ther; 2005 Oct; 22(7):613-26. PubMed ID: 16181301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic inhibitors of tumor necrosis factor in Crohn's disease.
    Ganesan S; Travis SP; Ahmad T; Jazrawi R
    Curr Opin Investig Drugs; 2002 Sep; 3(9):1301-6. PubMed ID: 12498004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy of Crohn's disease.
    van Montfrans C; Camoglio L; van Deventer SJ
    Mediators Inflamm; 1998; 7(3):149-52. PubMed ID: 9705600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease.
    Candon S; Mosca A; Ruemmele F; Goulet O; Chatenoud L; Cézard JP
    Clin Immunol; 2006 Jan; 118(1):11-9. PubMed ID: 16125467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of Crohn's disease with anti-TNF alpha].
    Lémann M
    Rev Prat; 1998 May; 48(10):1049-50. PubMed ID: 9781146
    [No Abstract]   [Full Text] [Related]  

  • 12. A chimeric anti-TNFalpha monoclonal antibody (cA2) in vivo removes TNFalpha-producing cells in Crohn's disease.
    Urra JM; Arteta M; Gómez-Caturla A; García-Durán F
    Hum Antibodies; 2001; 10(2):91-4. PubMed ID: 11673664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Infliximab--practical guidelines for the treatment of Crohn's disease].
    Bauerfeind P; Beglinger C; Beltinger J; Braegger C; Eigenmann F; Fried M; Guyot J; Hürlimann R; Michetti P; Seibold F; Straumann A
    Rev Med Suisse; 2006 Jul; 2(74):1807-15. PubMed ID: 16927560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infliximab use in luminal Crohn's disease.
    Richter JA; Bickston SJ
    Gastroenterol Clin North Am; 2006 Dec; 35(4):775-93. PubMed ID: 17129813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Crohn's disease: a still tourbillon of etiopathogenetic theories and therapeutic strategies. Some implications in the field of urology].
    Alberti C
    G Chir; 2010 Mar; 31(3):124-33. PubMed ID: 20426926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor necrosis factor therapy in rat chronic granulomatous colitis: critical dose-timing effects on outcome.
    Videla S; García-Lafuente A; Antolín M; Vilaseca J; Guarner F; Crespo E; González G; Salas A; Malagelada JR
    J Pharmacol Exp Ther; 1998 Dec; 287(3):854-9. PubMed ID: 9864264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do anti-tumor necrosis factors induce response and remission in patients with acute refractory Crohn's disease? A systematic meta-analysis of controlled clinical trials.
    Rahimi R; Nikfar S; Abdollahi M
    Biomed Pharmacother; 2007 Jan; 61(1):75-80. PubMed ID: 17184965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infliximab therapy in Crohn's disease: safety issues.
    Hommes DW; van Deventer SJ
    Neth J Med; 2003 Apr; 61(4):100-4. PubMed ID: 12852717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease.
    Ainsworth MA; Bendtzen K; Brynskov J
    Am J Gastroenterol; 2008 Apr; 103(4):944-8. PubMed ID: 18028512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review article: Infliximab therapy for inflammatory bowel disease--seven years on.
    Rutgeerts P; Van Assche G; Vermeire S
    Aliment Pharmacol Ther; 2006 Feb; 23(4):451-63. PubMed ID: 16441465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.